Incyte CORP Form 4 insider transactions

EVP and GM of Dermatology US, Matteo Trotta, reports disposition of Incyte Corp common stock to cover tax obligations.

Barry Flannelly, EVP & General Manager US at Incyte Corp, reports disposing of common stock on March 14, 2025.

Sheila Denton, EVP & General Counsel of Incyte Corp, reports the acquisition and disposal of common stock and the exercise of employee stock options.

Sheila Denton, EVP & General Counsel of Incyte Corp, reports the exercise of stock options and subsequent sale of shares on February 26, 2025.

Michael James Morrissey, EVP, Head of Tech. Operations at Incyte Corp, reports the acquisition of 10,552 shares of common stock through a restricted stock unit (RSU) award on January 31, 2025.

EVP, Head of Incyte International, Lee Heeson, reports acquisition of restricted stock units and updates beneficial ownership of Incyte Corp shares.

Paula Swain, EVP of Human Resources at Incyte Corp, reports the acquisition of stock options exercisable beginning January 17, 2025.

Incyte Corp's Executive Vice President, Vijay K Iyengar, was granted 14,772 stock options on January 17, 2025, which vest over a three-year period.

Incyte Corp's EVP & Chief Financial Officer, Christiana Stamoulis, has been granted 25,516 employee stock options.

An Incyte Corp executive has been granted a substantial stock option package, signaling potential confidence in the company's future performance.

Incyte CEO Herve Hoppenot was granted 55,510 stock options, exercisable starting January 17, 2025, according to a recent SEC filing.

Principal Accounting Officer Tray Thomas acquired 3,432 employee stock options in Incyte Corp on January 17, 2025, exercisable in installments starting July 15, 2025.

Pablo J. Cagnoni, President of R&D at Incyte Corp, was granted stock options exercisable beginning January 17, 2025.

Sheila A. Denton, EVP & General Counsel of Incyte Corp, reports the acquisition of employee stock options.

EVP and GM of Dermatology US, Matteo Trotta, acquired stock options in Incyte Corp.

Steven H. Stein, EVP & Chief Medical Officer of Incyte Corp, reported the sale of 12,352 shares of common stock and the grant of options to purchase 28,202 shares.

Michael Morrissey, EVP, Head of Tech. Operations at Incyte Corp, reports disposition of shares to cover tax obligations.

Barry P. Flannelly, an Executive Vice President at Incyte Corp, sold 3,158 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Michael Morrissey, EVP at Incyte Corp, reported a transaction involving the withholding of shares to cover tax obligations.

Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reported the withholding of 3,672 shares of common stock to cover tax obligations.

Executive Vice President and Chief Medical Officer of Incyte Corp, Steven H. Stein, reports the disposal of 10,692 shares to cover tax obligations.

Mohamed Khairie Issa, an executive at Incyte Corp, was granted 48,671 restricted stock units that vest over four years.

Baker Bros. Advisors LP and related entities, including Julian and Felix Baker, report changes in beneficial ownership of Incyte Corp stock due to director retainer fees and indirect ownership interests.

Director Paul J. Clancy acquired 331 shares of Incyte stock and holds 19,713 shares, including unvested restricted stock units.

Director Edmund Harrigan of Incyte Corp. reports acquiring 339 shares and holding 17,071 shares of common stock, including unvested restricted stock units.

Incyte Corp's Principal Accounting Officer, Thomas Tray, sold 1,300 shares of common stock in two separate transactions.

Incyte's EVP of Human Resources, Paula J. Swain, reported a transaction involving the withholding of shares to cover tax obligations, resulting in a net decrease in her direct holdings.

An Incyte Corp executive sold shares to cover tax obligations related to the vesting of restricted stock units and performance shares.

Incyte's Executive Vice President, Vijay K. Iyengar, sold a total of 6,043 shares of common stock in a recent transaction.

EVP & General Manager US of Incyte Corp, Barry P Flannelly, reports acquisition and disposal of common stock on November 6, 2024, according to a Form 4 filing with the SEC.